SCHEMBL22290609

SCHEMBL22290609

CN1C(=O)CCCc2ccc(Br)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 2/20 0.46
CASP2 P42575 1/20 0.43
TRPV1 Q8NER1 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
NFKB1 P19838 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
HIF1A Q16665 1/20 0.40
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30832142 1.00 SRD5A1 (0.46) SRD5A1CASP2TRPV1CYP1A2CYP3A4
SCHEMBL17419131 0.90 SRD5A1 (0.55) SRD5A1CASP2TRPV1CYP1A2CYP3A4
SCHEMBL31597788 0.90 SRD5A1 (0.55) SRD5A1CASP2TRPV1CYP1A2CYP3A4
SCHEMBL30832131 0.87 BMPR1B (0.49) SRD5A1CASP2CYP1A2GABRA1GABRG2
SCHEMBL19224681 0.87 BMPR1B (0.49) SRD5A1CASP2CYP1A2GABRA1GABRG2
SCHEMBL10196915 0.81 ALDH1A1 (0.51) SRD5A1HDAC1HDAC6BMPR1BBMPR1A
SCHEMBL290257 0.81 IDO1 (0.47) SRD5A1CASP2CYP1A2CYP3A4CYP2D6
SCHEMBL30683070 0.81 IDO1 (0.47) SRD5A1CASP2CYP1A2CYP3A4CYP2D6
SCHEMBL15965382 0.80 SRD5A1 (0.46) SRD5A1TRPV1HDAC1HDAC6BMPR1B
SCHEMBL2062210 0.80 ATAD2 (0.44) HSD17B3BMPR1BBMPR1ATGFBR1ACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368633-A1 AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF ARTIVILA BIOPHARMA (CN) 2025-12-04 US disclosed
EP-4582414-A1 AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF Artivila Biopharma (CN) 2025-07-09 EP disclosed
WO-2025090514-A1 COVALENT SARM1 INHIBITORS NURA BIO, INC. (US) 2025-05-01 WO disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 CN disclosed
US-20230167129-A1 HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2023-06-01 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SRD5A1 2322/4885CASP2 2052/4885TRPV1 4772/4885
US-20250368633-A1 AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF RIPK1, RIPK2, RIPK4 SRD5A1 3586/4885CASP2 455/4885TRPV1 4024/4885
US-20230167129-A1 HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF RIPK1, RIPK3, RIPK4 SRD5A1 2857/4885CASP2 1415/4885TRPV1 2441/4885
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL SRD5A1 112/4885CASP2 1314/4885TRPV1 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.